Novartis plans to develop tislelizumab in combination with other agents in its pipeline and will commercialize the drug if it garners approval in these regions.
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
Kymriah and Yescarta were evaluated in indolent NHL subtypes, and Yescarta was evaluated in the front-line setting for high-risk large B-cell lymphoma.
The firm is exploring whether the regimen may work for subgroups of patients with high TMB based on promising signals from the current failed analysis.
